证券记录 · 已归档季度
AZN
AstraZeneca PLC · Healthcare · Drug Manufacturers - General
20被追踪持有人
n/aΔ持有人
172.48M持有股份
$13.45B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 3.19M | $514.55M | n/a | −2 |
| Q2 2026 | 154 | +6 | 584.53M | $109.90B | +11 | −6 |
| Q1 2026 | 151 | +2 | 571.10M | $111.81B | +21 | −20 |
| Q4 2025 | 148 | 0 | 438.95M | $40.35B | +2 | −1 |
| Q3 2025 | 24 | 0 | 219.30M | $16.82B | +1 | −2 |
| Q2 2025 | 22 | -1 | 189.68M | $13.26B | n/a | −1 |
| Q1 2025 | 21 | 0 | 171.06M | $12.57B | n/a | n/a |
| Q4 2024 | 21 | +3 | 174.28M | $11.42B | +3 | n/a |
| Q3 2024 | 17 | -3 | 166.39M | $12.97B | n/a | −3 |
| Q2 2024 | 20 | n/a | 172.48M | $13.45B | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 64.94M | n/a | $5.06B | 0.6% | n/c | 1 | SEC ↗ ×2 |
| 2 | PRIMECAP Management ✦ | 42.60M | n/a | $3.32B | 2.4% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 40.57M | n/a | $3.16B | 0.6% | n/c | 1 | SEC ↗ ×8 |
| 4 | Fisher Asset Management ✦ | 9.96M | n/a | $776.47M | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Capital World Investors ✦ | 6.25M | n/a | $487.65M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Soros Fund Management ✦ | 2.45M | n/a | $191.20M | 5.9% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 2.29M | n/a | $178.48M | 0.4% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 617.71K | n/a | $48.17M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 587.36K | n/a | $45.81M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 498.95K | n/a | $38.91M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (被动) | 492.18K | n/a | $38.38M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 346.47K | n/a | $27.02M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 261.33K | n/a | $20.38M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 209.18K | n/a | $16.31M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Dodge & Cox ✦ | 149.78K | n/a | $11.68M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Norges Bank ✦ (被动) | 120.79K | n/a | $9.42M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 57.50K | n/a | $4.48M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 33.35K | n/a | $2.60M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 32.65K | n/a | $2.55M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 13.69K | n/a | $1.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1,307 持有人, 729.50M 股份, $139.69B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
Aug 08
Sharma Mani
Officer · See Remarks · 20 股 @ 160.57 · $3,249
公开市场卖出 (S)
在我们的覆盖窗口内无内部人士公开市场卖出记录。
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据